3-氯-7,8-二氢喹啉-5(6H)-酮 | 127724-75-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 3-氯-7,8-二氢喹啉-5(6H)-酮
• 英文名称: 3-chloro-7,8-dihydroquinolin-5(6H)-one
• 英文别名: 3-chloro-7,8-dihydro-6H-quinolin-5-one
• CAS: 127724-75-8
• 化学式: C₉H₈ClNO
• mdl: MFCD10696330
• 分子量: 181.622
• InChiKey: RKZNIWFFGNBOLH-UHFFFAOYSA-N

物化性质

• 沸点：
  298.4±40.0 °C(Predicted)
• 密度：
  1.316±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  30
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933499090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  3-氯-7,8-二氢喹啉-5(6H)-酮 在 甲醇 、 sodium tetrahydroborate 、 二苯基膦叠氮化物 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 反应 2.25h， 生成 5-azido-3-chloro-5,6,7,8-tetrahydroquinoline
  参考文献：
  名称：

  EP3401309

  摘要：

  公开号：
• 作为产物：
  描述：

  3-bromo-5-chloro-2-<4-<(tetrahydro-2H-pyran-2-yl)oxy>butyl>pyridine 在 jones reagent 、 叔丁基锂 、 4-甲基苯磺酸吡啶 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 乙醇 、 二氯甲烷 、 异丙醚 、 丙酮 为溶剂， 反应 6.75h， 生成 3-氯-7,8-二氢喹啉-5(6H)-酮
  参考文献：
  名称：

  Azatetralone synthesis via regioselective Grignard coupling and Parham cyclization

  摘要：

  DOI：

  10.1021/jo00028a070

文献信息

• [EN] SPIROPYRROLIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE<br/>[FR] INHIBITEURS DE BÊTA-SÉCRÉTASE DE TYPE SPIROPYRROLIDINE POUR LE TRAITEMENT DE LA MALADIE D'ALZHEIMER
  申请人：MERCK SHARP & DOHME

  公开号：WO2010094242A1

  公开（公告）日：2010-08-26

  The present invention is directed to spiropyrrolidine compounds of formula (I) which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.

  本发明涉及式(I)的螺环吡咯烷化合物，它们是β-分泌酶的抑制剂，并且在治疗涉及β-分泌酶的疾病，如阿尔茨海默病中有用。该发明还涉及包含这些化合物的药物组合物，以及在治疗涉及β-分泌酶的这类疾病中使用这些化合物和组合物。
• [EN] METABOTROPIC GLUTAMATE RECEPTOR MODULATORS<br/>[FR] MODULATEURS DES RÉCEPTEURS MÉTABOTROPES AU GLUTAMATE
  申请人：MERZ PHARMA GMBH & CO KGAA

  公开号：WO2012052451A1

  公开（公告）日：2012-04-26

  The invention relates to heterocyclic derivatives of formula (I) as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are mGluR5 modulators and are therefore useful for the control and prevention of acute and/or chronic neurological disorders wherein Y, W, R1, R2 and R3 are as defined in claim 1.

  该发明涉及公式（I）的杂环衍生物及其药学上可接受的盐。该发明还涉及制备这类化合物的方法。该发明的化合物是mGluR5调节剂，因此对于控制和预防急性和/或慢性神经系统疾病是有用的，其中Y、W、R1、R2和R3如权利要求1中所定义。
• Novel resolution process for racemic spiro-hydantoins
  申请人：Pfizer Inc.

  公开号：US04952694A1

  公开（公告）日：1990-08-28

  A novel three-step process for resolving a racemic spiro-hydantoin compound into its optical antipodes is disclosed, which involves (1) reacting said racemic compound with an optically-active asymmetric isocyanate of the formula RNCO, wherein R is (S)- or (R)-1-phenylethyl or (S) or (R)-1-(1-naphthyl)ethyl, to form the corresponding diastereomeric uredio compound; (2) separating the resulting diastereomeric mixture into its component parts, and (3) thereafter converting the separated ureido diastereomers obtained in step (b) to the corresponding asymmetric hydantoin compounds by treatment with an alkali metal lower alkoxide (C.sub.1 -C.sub.4), followed by acidification, whereupon the desired optical isomer is obtained. The final products so obtained, such as (4S)-(+)-6-fluoro-2,3-dihydro-spiro[4H-1-benzopyran-4,4'-imidazolidine]-2' , 5'-dione (sorbinil) and (5'S)-3'-chloro-5', 6', 7', 8'-tetra-hydro-spiro[imidazolidine-4,5'-quinoline]-2,5-dione, are known to be useful in preventing or alleviating certain chronic diabetic complications. The aforementioned diastereomeric uredio intermediates are novel compounds.

  揭示了一种用于将一个混合氨基酸螺环脲化合物分离成其光学对映体的新颖三步过程，包括(1)将该混合氨基酸与一种光学活性不对称异氰酸酯（化学式为RNCO，其中R为(S)-或(R)-1-苯乙基或(S)或(R)-1-(1-萘基)乙基）反应，形成相应的二对映异构脲化合物；(2)将得到的二对映混合物分离成其组分；(3)然后通过用碱金属低碱度物（C.sub.1 -C.sub.4）处理，随后酸化，将在步骤(2)中获得的分离的脲二对映异构体转化为相应的不对称螺环脲化合物，从而得到所需的光学异构体。因此获得的最终产品，如(4S)-(+)-6-氟-2,3-二氢-螺[4H-1-苯并吡喃-4,4'-咪唑烷]-2'，5'-二酮（索必林）和(5'S)-3'-氯-5',6',7',8'-四氢-螺[咪唑烷-4,5'-喹啉]-2,5-二酮，已知在预防或缓解某些慢性糖尿病并发症方面具有用途。上述二对映异构脲中间体是新颖的化合物。
• Reactivators Of Organophosphorous Inhibited Acetylcholinesterase
  申请人：Southwest Research Institute

  公开号：US20140350262A1

  公开（公告）日：2014-11-27

  The present invention relates to organophosphate-inhibited acetylcholinesterase (AChE) reactivators with central nervous system (CNS) bioavailability and their associated methods of preparation including their use for treatment of exposure to AChE inhibitors such as an organophosphate (OP) insecticides and nerve agents.

  本发明涉及具有中枢神经系统（CNS）生物利用度的有机磷酸酯抑制的乙酰胆碱酯酶（AChE）再活化剂及其相关制备方法，包括它们用于治疗暴露于AChE抑制剂，如有机磷酸酯（OP）杀虫剂和神经毒剂的方法。
• Preparation of optically active spiro-hydantoins
  申请人：Pfizer Inc.

  公开号：US05206367A1

  公开（公告）日：1993-04-27

  This invention relates to the preparation of preparing optically-active asymmetric spiro-hydantoin compounds, which are known to be of value in the medical control of certain chronic diabetic complications arising from diabetes mellitus. This invention also includes within its scope certain corresponding novel amino and hydantoic acid compounds and the cinchonine salt of optically active hydantoic acid, which are used as intermediates in the aforesaid process.

  本发明涉及制备光学活性不对称螺内酰脲化合物的制备，这些化合物已知在医疗控制由糖尿病引起的某些慢性糖尿病并发症方面具有价值。本发明还包括某些相应的新型氨基和脲酸化合物以及光学活性脲酸奎宁盐，这些化合物用作上述过程中的中间体。